Teladoc Health, Inc. (0LDR.L)
USD 7.3
(3.11%)
USD 7.3
(3.11%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 153.99 Million USD | -98.57% |
| 2022 | -13.38 Billion USD | 94428.21% |
| 2021 | -84.67 Million USD | 95.8% |
| 2020 | -438.01 Million USD | -1078.03% |
| 2019 | -41.49 Million USD | 4.91% |
| 2018 | -35.25 Million USD | 29.56% |
| 2017 | -70.42 Million USD | 9.13% |
| 2016 | -62.84 Million USD | 6.85% |
| 2015 | -50.92 Million USD | -296.9% |
| 2014 | -12.83 Million USD | -150.83% |
| 2013 | -5.11 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 49.66 Million USD | -2805.57% |
| 2024 Q3 | -44.4 Million USD | 108.91% |
| 2024 Q1 | 23.42 Million USD | -66.99% |
| 2023 Q1 | 24.51 Million USD | -99.36% |
| 2023 Q3 | 40.39 Million USD | 29.68% |
| 2023 Q2 | 31.14 Million USD | 27.07% |
| 2023 FY | - USD | -98.57% |
| 2023 Q4 | -257.57 Million USD | -737.71% |
| 2022 Q3 | -6.27 Million USD | -219.13% |
| 2022 Q1 | -1.27 Million USD | -106.44% |
| 2022 FY | - USD | 94428.21% |
| 2022 Q4 | 3.82 Billion USD | 61140.48% |
| 2022 Q2 | -1.96 Million USD | -54.56% |
| 2021 FY | - USD | 95.8% |
| 2021 Q2 | -12.22 Million USD | 39.72% |
| 2021 Q3 | -1.54 Million USD | 87.39% |
| 2021 Q4 | 19.75 Million USD | 1381.89% |
| 2021 Q1 | -20.27 Million USD | 94.38% |
| 2020 FY | - USD | -1078.03% |
| 2020 Q4 | -360.89 Million USD | -2040.1% |
| 2020 Q3 | 18.6 Million USD | 216.63% |
| 2020 Q2 | 5.87 Million USD | 196.01% |
| 2020 Q1 | -6.11 Million USD | -89.8% |
| 2019 Q4 | -3.22 Million USD | 50.64% |
| 2019 Q2 | -10 Million USD | 2.96% |
| 2019 FY | - USD | 4.91% |
| 2019 Q1 | -10.31 Million USD | -50.63% |
| 2019 Q3 | -6.53 Million USD | 34.73% |
| 2018 Q4 | -6.84 Million USD | -16.55% |
| 2018 Q2 | -8.37 Million USD | 9.7% |
| 2018 Q3 | -5.87 Million USD | 29.83% |
| 2018 FY | - USD | 29.56% |
| 2018 Q1 | -9.27 Million USD | 36.51% |
| 2017 Q3 | -6.59 Million USD | 32.07% |
| 2017 Q1 | -12.19 Million USD | -14.69% |
| 2017 FY | - USD | 9.13% |
| 2017 Q2 | -9.71 Million USD | 20.37% |
| 2017 Q4 | -14.6 Million USD | -121.31% |
| 2016 Q1 | -13.2 Million USD | -3.18% |
| 2016 FY | - USD | 6.85% |
| 2016 Q4 | -10.63 Million USD | 7.17% |
| 2016 Q3 | -11.45 Million USD | 11.24% |
| 2016 Q2 | -12.9 Million USD | 2.29% |
| 2015 Q4 | -12.8 Million USD | -15.27% |
| 2015 Q2 | -15.32 Million USD | -31.12% |
| 2015 Q1 | -11.69 Million USD | -110.82% |
| 2015 Q3 | -11.1 Million USD | 27.56% |
| 2015 FY | - USD | -296.9% |
| 2014 Q2 | -2.3 Million USD | -29.88% |
| 2014 Q4 | -5.54 Million USD | -72.9% |
| 2014 Q1 | -1.77 Million USD | 0.0% |
| 2014 FY | - USD | -150.83% |
| 2014 Q3 | -3.2 Million USD | -39.19% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Phreesia, Inc. | -102.94 Million USD | 249.592% |
| Accuray Incorporated | 9 Million USD | -1609.368% |
| Align Technology, Inc. | 799.03 Million USD | 80.727% |
| Elevance Health Inc. | 10.49 Billion USD | 98.532% |
| AxoGen, Inc. | -13.32 Million USD | 1255.44% |
| Boston Scientific Corporation | 3.61 Billion USD | 95.738% |
| CVS Health Corporation | 18.17 Billion USD | 99.153% |
| Cardinal Health, Inc. | 1.97 Billion USD | 92.215% |
| Centene Corporation | -463 Million USD | 133.261% |
| DaVita Inc. | 2.34 Billion USD | 93.437% |
| HCA Healthcare, Inc. | 12.72 Billion USD | 98.789% |
| Hologic, Inc. | 1.29 Billion USD | 88.119% |
| Humana Inc. | -561 Million USD | 127.45% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 87.353% |
| Laboratory Corporation of America Holdings | 1.34 Billion USD | 88.588% |
| Masimo Corporation | 236.7 Million USD | 34.94% |
| McKesson Corporation | 4.66 Billion USD | 96.7% |
| Patterson Companies, Inc. | 374.75 Million USD | 58.907% |
| Quest Diagnostics Incorporated | 1.73 Billion USD | 91.109% |
| ResMed Inc. | 1.6 Billion USD | 90.377% |
| Henry Schein, Inc. | 943 Million USD | 83.669% |
| Universal Health Services, Inc. | 1.74 Billion USD | 91.167% |
| Veeva Systems Inc. | 429.33 Million USD | 64.131% |
| Baxter International Inc. | 2.77 Billion USD | 94.453% |
| Becton, Dickinson and Company | 4.27 Billion USD | 96.398% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 93.568% |
| Danaher Corporation | 7.49 Billion USD | 97.946% |
| Stryker Corporation | 5.16 Billion USD | 97.016% |
| Medtronic plc | 9.05 Billion USD | 98.3% |